Mark J Giganti Selected Research

Therapeutics

11/2023	Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.
10/2023	One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.
3/2023	Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials.
1/2023	Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials.
1/2023	Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.
1/2018	Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation.
4/2010	Association between weight gain and clinical outcomes among malnourished adults initiating antiretroviral therapy in Lusaka, Zambia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark J Giganti Research Topics

Disease

10	COVID-19 05/2024 - 01/2023
4	HIV Infections (HIV Infection) 01/2021 - 10/2011
2	Inflammation (Inflammations) 02/2024 - 01/2022
2	Acquired Immunodeficiency Syndrome (AIDS) 01/2018 - 01/2018
1	Disease Progression 05/2024
1	Infections 10/2023
1	Viremia 01/2021
1	Cholera 01/2014
1	Tuberculosis (Tuberculoses) 08/2011
1	Stillbirth 05/2011
1	Birth Weight (Birth Weights) 07/2010
1	Weight Gain 04/2010

Drug/Important Bio-Agent (IBA)

5	Monoclonal AntibodiesIBA 05/2024 - 01/2023
5	RNA (Ribonucleic Acid)IBA 10/2023 - 01/2021
4	Antiviral Agents (Antivirals)IBA 05/2024 - 01/2023
3	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2021
2	amubarvimabIBA 05/2024 - 01/2023
2	romlusevimabIBA 05/2024 - 01/2023
1	Zidovudine (Retrovir)FDA LinkGeneric 02/2024
1	ogalvibartIBA 01/2024
1	crexavibartIBA 01/2024
1	camostatIBA 10/2023
1	Immunoglobulins (Immunoglobulin)IBA 01/2023
1	SAB-185IBA 01/2023
1	tixagevimabIBA 01/2023
1	cilgavimabIBA 01/2023
1	VaccinesIBA 01/2023
1	Immunoglobulin G (IgG)IBA 01/2023
1	NucleosidesIBA 01/2018
1	Reverse Transcriptase InhibitorsIBA 01/2018
1	WastewaterIBA 01/2014
1	Hemoglobins (Hemoglobin)IBA 08/2011
1	Indicators and Reagents (Reagents)IBA 05/2011
1	Nevirapine (Viramune)FDA Link 07/2010

Therapy/Procedure

7	Therapeutics 11/2023 - 04/2010
5	Art Therapy 01/2021 - 04/2010
1	Intravenous Administration 01/2024
1	Continuity of Patient Care 01/2016
1	Highly Active Antiretroviral Therapy (HAART) 10/2011
1	Prenatal Care (Care, Prenatal) 07/2010